ClinicalTrials.gg
Not yet recruitingNCT07748247SWAPUpdated Aug 5, 2026

Swap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery

A Phase 4 interventional study of Desflurane and Sevoflurane-Desflurane in Obesity and Bariatric Surgery, sponsored by Clínica Dávila. Not yet recruiting at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Clínica Dávila · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Obesity with a site in Chile — 10 open to participants now, 13 under way, 3 of them phase 3. Obesity · Chile.

Planned enrollment
20th of 42
82 · median 75
Started
2026
with 2 others
Phase 4
6 of 47
1 open now
Primary completion
2027-04
later than 7 of 12 live
Registered
46th of 47
by date

Among the 47 studies in Obesity with a site in Chile, this one is the 20th largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 46th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 47 studies in Obesity with a site in Chile are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Chile have not opened yet or have stopped. Only those recruiting at a site in Chile →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Obesity with a site in Chile, or all of them as a file.
02

Study summary

This randomized, parallel-group, non-inferiority clinical trial aims to evaluate whether an anesthetic swap strategy consisting of sevoflurane followed by desflurane 30 minutes before the end of surgery is non-inferior to continuous desflurane anesthesia with respect to extubation time in adults undergoing elective laparoscopic bariatric surgery. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8, incidence of postoperative nausea and vomiting, post-anesthesia care unit length of stay, and desflurane-related costs.

Read the detailed description

Obesity is associated with an increased risk of postoperative respiratory complications, making rapid and safe anesthetic recovery particularly important in patients undergoing bariatric surgery. Desflurane provides rapid emergence because of its favorable pharmacokinetic profile but is associated with higher cost and greater environmental impact than sevoflurane.

This prospective, randomized, parallel-group, non-inferiority trial will compare two inhalational anesthetic strategies in adults undergoing elective laparoscopic bariatric surgery at Clínica Dávila. Participants will be randomly assigned in a 1:1 ratio to receive either continuous desflurane throughout the procedure or a swap strategy consisting of sevoflurane during most of the operation followed by desflurane beginning 30 minutes before surgical closure.

The primary outcome is extubation time, defined as the interval from discontinuation of inhaled anesthetic agents to removal of the endotracheal tube. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8 in the post-anesthesia care unit, incidence of postoperative nausea and vomiting, length of stay in the post-anesthesia care unit, and desflurane-related costs. The study is designed to determine whether the swap anesthetic strategy is non-inferior to continuous desflurane while reducing desflurane consumption, with potential benefits for environmental sustainability and healthcare costs.

03

Conditions studied

  • Obesity
  • Bariatric Surgery

Browse trials for

Keywords

  • Desflurane
  • Sevoflurane
  • General Anesthesia
  • Bariatric Surgery
  • Extubation Time
  • Obesity
  • Laparoscopic Gastric Bypass
  • Randomized Trial
  • Non-Inferiority Trial
  • Patient State Index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Scheduled for elective laparoscopic gastric bypass surgery.
  • between 30 and 50 kg/m².
  • physical status II or III.
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Surgical procedure lasting less than 2 hours.
  • greater than 50 kg/m².
  • Significant cardiac disease.
  • Moderate or severe obstructive respiratory disease, including uncontrolled asthma or .
  • Pregnancy or breastfeeding.
  • Known allergy or to medications used during the intraoperative period.
  • Personal or family history of malignant hyperthermia.
  • Active illicit drug use or substance dependence.
  • Advanced chronic kidney disease, defined as an estimated below 60 mL/min.
  • Myasthenia gravis or another neuromuscular junction disorder.
  • Severe cognitive or psychiatric disorder.
  • Refusal to participate or withdrawal of at any time.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Continuous Desflurane

    Participants receive desflurane as the inhalational anesthetic throughout the entire elective laparoscopic bariatric surgery according to the study protocol.

    Drug: Desflurane

  • Experimental
    Sevoflurane-Desflurane Swap

    Participants receive sevoflurane during most of the procedure and are switched to desflurane 30 minutes before the end of surgery according to the study protocol.

    Drug: Sevoflurane-Desflurane

Interventions

  • Desflurane administered as the inhalational anesthetic throughout the surgical procedure.

  • DrugSevoflurane-Desflurane

    Sevoflurane administered during the initial phase of surgery followed by desflurane beginning 30 minutes before surgical closure.

06

What researchers measure

Primary outcomes

  1. Extubation Time

    Time in seconds from discontinuation of inhaled anesthetic agents to removal of the endotracheal tube.

    Time frame: Perioperative

Secondary outcomes

  1. Time to Achieve Patient State Index Greater Than 80

    Time in seconds from discontinuation of inhaled anesthetic agents until the Patient State Index (PSi) reaches a value greater than 80.

    Time frame: Perioperative

  2. Postoperative Nausea and Vomiting

    Presence of postoperative nausea or vomiting, recorded as a binary outcome of yes or no.

    Time frame: Up to 24 hours after surgery

  3. Time to Achieve an Aldrete Score of at Least 8

    Time in minutes from arrival at the post-anesthesia care unit until the participant achieves an Aldrete score of at least 8 out of 10.

    Time frame: Up to 24 hours after surgery

  4. Time to Post-Anesthesia Care Unit Discharge Readiness

    Time in minutes from arrival at the post-anesthesia care unit until the participant meets the institutional discharge criteria.

    Time frame: Up to 24 hours after surgery

  5. Desflurane-Related Cost

    Estimated cost in Chilean pesos associated with desflurane use. The cost will be calculated according to the total duration of desflurane administration, using an estimated consumption of 0.75 mL per minute and a cost of 415 Chilean pesos per mL. The applied formula will be: duration of desflurane anesthesia in minutes multiplied by 311.25 Chilean pesos.

    Time frame: Periprocedural (during surgery)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available because the study involves clinical data collected at a single institution, and no data-sharing agreement or repository has been established. Only aggregate study results will be reported in scientific publications and presentations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 8 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Aug 5, 2026
StartEst.
Aug 3, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07748247
Lead sponsor
Clínica Dávila
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Magdalena Estefo, MD
Contact
magdalenaestefo@gmail.com
+56 9 7986 5505

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desflurane

Start the discussion